Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Syndax Pharmaceuticals reported a quarterly loss of $1.10 per share, slightly worse than the Zacks Consensus Estimate of a loss of$1.08, and compared to a loss of $1 per share a year ago, indicating a decline in performance [1] - The company posted revenues of$7.68 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 65.45%, while revenues were zero a year ago [2] - Over the last four quarters, Syndax has surpassed consensus EPS estimates three times, showing some volatility in earnings performance [2] Stock Movement and Outlook - Syndax shares have increased approximately 18.3% since the beginning of the year, outperforming the S&P 500's gain of 1.2% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the earnings outlook for the upcoming quarters [3][4] - Current consensus EPS estimate for the next quarter is -$1.14 on revenues of$8.1 million, and for the current fiscal year, it is -$4.25 on revenues of$71.56 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Syndax belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Syndax's stock performance [5][6]